nandrolone phenpropionate (Durabolin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women. It is given by injection into muscle once every week. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Parenteral
  • Pro Drug: Yes

Alternative names

17 beta-hydroxyestr-4-en-3-one 17-decanoate | 17 beta-hydroxyestr-4-en-3-one hydrocinnamate | 17-hydroxyestr-4-en-3-one | 19-nor-4-androstene-17 beta-ol-3-one 17-decanoate | 19-norandrostendione | 19-nortestosterone | 19-nortestosterone decanoate | 19ntpp | decadurabolin | deca-durabolin | decadurobolin | durabolin | fenobolin | hybolin decanoate | menidrabol | nadrolone phenylpropionate | nandrolon | nandrolone | nandrolone 17β-decanoate | nandrolone ciii | nandrolone decanoate | nandrolone phenpropionate | nandrolone phenpropionate, (17alpha)-isomer | nandrolone phenylpionate | nandrolone phenylpropionate | nandrolon phenylpropionate | nerobolil | nerobolyl | norandrolone phenylpropionate | norandrolone phenyl propionate | norandrostenolon | norandrostenolone | norandrostenolone decanoate | norandrostenolone phenylpropionate | nortestonate | nortestosterone | nortestosterone decanoate | nortestosterone furanpropionate | nortestosterone phenylpropionate | npp | nsc-23162e | ntpp | oestrenolon | retabolil | retabolyl

Organizations (26)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Anemia (approved 1959)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Anemia, Aplastic (Phase 3)

Bone Marrow Failure Disorders (Phase 1/Phase 2)

Critical Illness (Phase 2)

Hematologic Diseases (Phase 3)

Hip Fractures (Phase 2)

HIV Infections (Phase 1)

HIV Wasting Syndrome (Phase 1)

Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)

Malnutrition (Phase 2)

Pancytopenia (Phase 3)

Sarcopenia (Phase 2)

Spinal Cord Injuries (Phase 2)

Sports Medicine (Phase 1/Phase 2)

Telomere Shortening (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue